,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny-04', 'congrat', 'thank you']
standing ovation for #asco22 plenary session destiny-04 study. we did it. congrats to the entire team. thank you for all the patients who have participated. 
MD Anderson Cancer Ctr, Breast Med Oncologist, Section Chief of Translational Breast Cancer Research, Executive Director of IBC Program